Overview of Extrontel Plus XL

Property	Description
Active Ingredients	Praziquantel, Pyrantel, Febantel
Form	Oral Tablet (often flavored)
Pharmacological Class	Broad-spectrum Anthelmintic
General Purpose	Comprehensive worm eradication
Origin	Synthetic Combination

Extrontel Plus XL is a synthetic origin, fixed-dose combination product specifically classified as a broad-spectrum anthelmintic in veterinary medicine, primarily formulated for canines. The medication is supplied as an oral tablet formulation, often designed to be flavored to enhance palatability for easy administration. As an antiparasitic agent, its main function is to eliminate internal parasitic worm infections. This combination is clinically recognized for its efficacy against common cestodes and nematodes.

Composition and Active Ingredient Strategy

The preparation contains three distinct active ingredients—Febantel, Praziquantel, and Pyrantel (often as Pyrantel embonate)—which represent three different pharmacological families. The strategic use of a triple combination achieves a powerful synergistic action, where the individual components enhance each other's effects against different parasite types. For instance, Praziquantel, a Pyrazinoisoquinoline derivative, is widely documented for its reliable action against cestodes (tapeworms). This tripartite composition ensures the formula is designed to quickly target major classes of flatworms and roundworms simultaneously.

General Therapeutic Purpose

The general therapeutic purpose of Extrontel Plus XL is comprehensive worm eradication, targeting cestodes and nematodes simultaneously. This triple-action approach is crucial for treating mixed parasitic infections, a typical scenario in companion animals. The distinct physiological actions of the ingredients, which include inducing paralysis, causing structural damage, and initiating energy deprivation, combine to deliver a robust and effective outcome against a wide range of internal parasites.

What side effects are possible with Extrontel Plus XL?

Possible side effects and safety information

The safety profile of the triple combination of Praziquantel, Pyrantel, and Febantel is officially documented by government regulatory agencies, focusing on specific categories of adverse reactions and high-level safety constraints.

Adverse Reaction Classification

The adverse reactions associated with this product are typically classified as Very Rare in regulatory documentation, meaning they are observed in fewer than 1 in 10,000 animals treated, including isolated reports. The documented effects are generally slight and transient.

System-Organ Class	Documented Effects
Gastrointestinal System Disorders	Vomiting (Emesis), Diarrhea
General Disorders	Lethargy, Anorexia, Hyperactivity

Population-Specific Constraints and Safety Notes

The product is contraindicated in animals with known hypersensitivity to any of the active substances or excipients, a safety marker for potential serious adverse consequences. Furthermore, the use of this anthelmintic is not recommended during the first 4 weeks of gestation, based on specific regulatory safety assessments.

Safety-Related Restrictions

Official regulatory labeling includes a high-level safety constraint: the product must not be administered simultaneously with Piperazine compounds. This restriction is documented to avoid the potential for pharmacological antagonism, which could compromise the intended therapeutic effect and introduce safety concerns. Additionally, due to the inclusion of Praziquantel, the product’s use requires adherence to specific guidelines from competent authorities regarding the handling of Echinococcus spp., which is recognized as a potential hazard for humans.

Overdose and Emergency Response

The overdose profile for the Praziquantel, Pyrantel, and Febantel combination is documented in official regulatory labeling, outlining specific clinical manifestations and mandated emergency actions. High-dose exposure, typically cited at five times the recommended level or greater, may result in adverse clinical signs. Documented manifestations include gastrointestinal distress such as vomiting, diarrhea, and loss of appetite (anorexia), alongside general systemic signs like lethargy and increased salivation. Of greater concern are the severe neurological manifestations listed in regulatory documents, including muscle tremors and the occurrence of seizures, which indicate acute toxicity to the Central Nervous System.

Emergency Actions Mandated by Regulators

Incident Type	Action Required (Label-Derived Phrasing)
Suspected Overdose	Immediately seek emergency veterinary care or contact an animal poison control center.
Accidental Human Ingestion	Seek immediate medical advice and show the product leaflet or label to the treating physician.

Official guidance confirms that no specific antidote is known for this overdose. Therefore, clinical management is restricted to symptomatic and supportive treatment tailored to the signs presented. Furthermore, special regulatory notes exist regarding population-specific risks: caution is advised against exceeding the dose in pregnant animals due to teratogenic risk, and use is generally not recommended in very young animals (e.g., puppies under 3 weeks old) due to increased sensitivity.

Therapeutic Uses of Extrontel Plus XL

What Extrontel Plus XL Treats: Main Uses and Benefits

Extrontel Plus XL is commonly used to provide essential symptomatic support in clinical settings marked by episodes of sudden symptom escalation. It is applied across domains where additional symptomatic support is needed. It is considered relevant for easing symptoms that may lead to temporary functional strain or discomfort and become temporarily overwhelming.

Management of Pronounced Discomfort

The medication is relevant for managing symptoms that interfere with daily comfort, including groups of symptoms that appear suddenly or fluctuate, and those that create noticeable physiological strain. It is applicable across conditions characterized by periods of heightened symptoms and is used in situations involving certain distressing manifestations. This assistance generally supports general well-being during symptomatic phases. This relief contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Pronounced Discomfort

Regulatory References

Health Canada's Anthelmintics Labelling Standard

Eligibility and Restrictions for Use

Who Can and Cannot Use Extrontel Plus XL?

Extrontel Plus XL is officially designated for use exclusively in dogs (canines), and eligibility is strictly defined by regulatory guidelines concerning age, weight, and specific medical conditions.

Absolute Contraindications

Regulatory documents mandate that the medicine must not be used in the following populations:

Classification	Restriction
Hypersensitivity	Animals with a known hypersensitivity to Praziquantel, Pyrantel, Febantel, or any excipients.
Pediatric Threshold	Dogs younger than 2 weeks of age.
Weight Threshold	Dogs weighing less than 2 kg.
Concomitant Drugs	Concurrent use with piperazine compounds is prohibited.

Population Restrictions and Eligibility

Official labeling defines specific restrictions related to reproductive status:

Pregnancy: Use is not recommended in bitches during the first 4 weeks of pregnancy. When treating pregnant animals, the official dose must not be exceeded.
Lactation: Use is permitted in bitches during the lactation period.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Extrontel Plus XL (a combination of Praziquantel, Pyrantel, and Febantel) identifies specific interactions with other medicinal products and substance classes, establishing mandatory restrictions and pharmacokinetic cautions.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interaction Type	Interacting Substance/Class	Official Regulatory Statement
Contraindicated Combination	Piperazine compounds	The co-administration of this drug with piperazine compounds is prohibited due to the risk of antagonism of the anthelmintic effects of the Pyrantel component.
Toxicity Risk	Other cholinergic compounds	Concurrent use is officially documented as potentially leading to signs of toxicity.
Metabolic/Exposure Modification	Cytochrome P-450 enzyme inducers (e.g., Dexamethasone, Phenobarbital)	These substances may increase enzyme activity, which is documented to result in a decrease in the plasma concentrations of the Praziquantel component.

Interaction-Related Constraints

The most significant interaction constraint is the mandatory prohibition on the simultaneous use of this product with piperazine compounds. This restriction is based on the documented risk of pharmacodynamic conflict. The interaction profile is thus structured around this mandatory use restriction and the pharmacokinetic caution involving metabolism by P-450 enzyme inducers.

Mechanism of Action

Extrontel Plus XL employs a triple-action strategy that targets three distinct biological pathways essential for parasite survival, which covers a wide range of parasite species.

Neuromuscular System Overload and Paralysis (Pyrantel)

This domain engages the parasite's cholinergic signaling by having Pyrantel act as a depolarizing agonist at specific nicotinic acetylcholine receptors ( nAChRs) in susceptible nematodes. This binding causes continuous, uncontrolled muscle stimulation, leading to spastic paralysis. This sustained contraction forces the worms to detach from the intestinal wall, resulting in their detachment from the intestinal wall.

Ion Flux Disruption and Structural Collapse (Praziquantel)

The mechanism mediated by Praziquantel rapidly modulates the flatworm's voltage-gated calcium channels, resulting in a massive, uncontrolled influx of Ca^2+ ions. This surge triggers immediate, widespread tetanic contraction and rapid structural damage (vacuolization) to the worm's outer protective layer, leading to the parasite's physiological and mechanical collapse.

Inhibition of Cellular Energy and Structural Assembly (Febantel)

Through its active metabolites, Febantel functions as a microtubule polymerization inhibitor, binding to the beta-Tubulin protein. This disrupts critical cellular processes, including glucose uptake and essential transport functions. The progressive inhibition leads to fatal depletion of the parasite's energy reserves ( ATP), creating a sustained mechanism that results in metabolic toxicity across various nematode species, including those where neuromuscular blockade is less effective.

Dosage and Administration Information

How to Use Extrontel Plus XL: Official Administration Guidelines

Extrontel Plus XL is administered strictly as a single, weight-based oral dose. The standardized usage pattern is defined by the fixed concentration of the three active ingredients (Praziquantel, Pyrantel, and Febantel) per unit of body weight.

Administration Details

The fundamental principle is to administer a minimum dose of 5 mg/kg Praziquantel, 5 mg/kg Pyrantel base, and 25 mg/kg Febantel in a single oral course. The actual dose is determined by selecting the appropriate number of tablets or tablet parts using a weight-band table provided on the product label. Accurate determination of the animal's body weight is an essential procedural requirement prior to administration.

Timing and Frequency

Extrontel Plus XL is primarily utilized as a short-term, single-administration course. General administration parameters establish that fasting is neither necessary nor recommended, permitting the tablet to be administered directly by mouth or disguised in a small amount of food. For specific risk scenarios, such as the control of Echinococcus multilocularis, the protocol may shift to a periodic, scheduled regimen of administration, typically at intervals of 21 to 26 days.

Population Restrictions

Labeled usage is subject to specific constraints based on age and reproductive status. The product is not approved for use in puppies younger than 3 weeks of age or those with a body weight under 0.9 kg (2 lbs). Furthermore, use is not recommended during the first four weeks of pregnancy.

Recent Clinical Evidence

Research evidence / Overview of studies for Extrontel Plus XL

The clinical evaluation of the combination in Extrontel Plus XL (Praziquantel, Pyrantel, and Febantel) was observed in studies including controlled research and larger field investigations. The body of evidence describes the extent of what has been studied so far, the patterns observed in research settings, and the areas where information remains limited.

Evidence for Use in Treating Major Intestinal Helminth Infections

Research has extensively explored the use of this combination for addressing common internal parasitic worms, specifically tapeworms (cestodes) and roundworms, hookworms, and whipworms (nematodes). The evidence base was evaluated in studies including Randomized Controlled Trials (RCTs) and Controlled Clinical Field Trials.

These studies monitored specific outcomes related to the parasite burden, examining Faecal Egg Count Reduction (FECR) and performing direct Worm Counts. Research describes patterns related to measured differences in worm counts between the treated and untreated groups. However, the evidence primarily focuses on study outcomes related to existing, confirmed infections. Data for prevention or long-term management of recurring infection are insufficient in the core regulatory studies, as trials relied on short-term observation periods.

Research Investigating Protozoan Parasite Cyst Excretion

Beyond the primary helminth indications, research has also examined the combination's use in settings involving the protozoan parasite Giardia. This evidence was observed in Controlled Field Studies and various Clinical Investigations.

Research has explored various administration schedules and studies monitored the change in the number of Giardia cysts shed in faecal samples. Findings show patterns related to variability in the measured absence of cyst excretion. Furthermore, the evidence was associated with the measured absence of cyst shedding coinciding with the implementation of concurrent environmental measures.

Long-Term Data and Follow-Up Duration in Studies

The core evidence for clearance relies heavily on short-term follow-up durations, typically ranging from 3 to 14 days post-treatment. There is limited information for long-term outcomes regarding the durability of parasite absence. Research is ongoing regarding patterns of re-infection or the evolution of parasite absence months after the initial administration.

Evidence in Study Populations and Subgroups

The main body of evidence was evaluated in studies conducted on Canines, including both dogs and puppies that meet minimum age and weight requirements. The evidence for certain groups remains insufficient. Data exploring how outcome measurements may vary across specific disease severity strata or animals with certain comorbidity-defined conditions are limited. The results apply only to the populations studied and may not provide full insight into every possible canine subgroup.

What Remains Unclear or Requires Further Research

The research exploring Giardia cyst excretion utilized studies where sample sizes were modest and evidence quality varies compared to the core helminth RCTs, meaning certainty remains low for this non-primary use. Data for certain specific subgroups, such as extremely young animals or those with complex concurrent health issues, remain insufficient. Research does not determine whether an individual will respond similarly across all possible variables; findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Extrontel Plus XL (FAQ)

Q: Why is Extrontel Plus XL taken only once a day?

Official information indicates that the active ingredients have different absorption and action profiles. One component, Pyrantel, is slowly absorbed to maximize its action in the gut. The other components are absorbed, and their active metabolites maintain concentration for a duration described by officials as suitable for a single-administration course.

Q: How long does it take for Extrontel Plus XL to start working?

The ingredients have different onset times. Regulatory documents describe that one component, Praziquantel, acts rapidly, causing paralysis almost instantly upon contact with the parasite. The active metabolites of Febantel deplete the parasite's energy, which regulatory evidence suggests results in the death of the parasite within two to three days after administration.

Q: What serious side effects should I watch out for with Extrontel Plus XL?

Official documentation classifies adverse reactions as very rare, occurring in fewer than 1 in 10,000 treatments, and are usually slight and temporary. However, official documentation includes a contraindication for animals with known hypersensitivity to the active substances, a safety marker for potential serious adverse consequences like severe allergic reactions.

Q: Can I take Extrontel Plus XL if I'm pregnant or breastfeeding?

According to the official product information, use is not recommended during the first four weeks of pregnancy. Regulatory documents state that use is allowed during the lactation period. When the medication is used in pregnant animals, the official stated dose must not be exceeded.

Q: How do I know if Extrontel Plus XL is working for me?

The drug works by eliminating parasites, though the signs of effectiveness may differ. Regulatory-based descriptions indicate that the action on roundworms causes paralysis, meaning these parasites may occasionally be observed in the feces within a day or so after treatment. For tapeworms, the component causes them to lose their structure and be digested, meaning whole tapeworms are very rarely seen.

Q: Is it normal to feel dizzy when first starting Extrontel Plus XL?

Dizziness is not explicitly listed in the regulatory documentation for this product's use. Official adverse reaction lists describe documented effects as being very rare, including gastrointestinal issues like vomiting and diarrhea, as well as general issues like lethargy or hyperactivity.

Q: Can Extrontel Plus XL affect my sleep?

The official documentation lists both lethargy (lack of energy) and hyperactivity as documented adverse reactions, though these effects are classified as very rare. These are high-level effects that could potentially influence the animal's normal sleep-wake cycle.

Q: What should I do if the side effects of Extrontel Plus XL are bothersome?

Regulatory-based summaries instruct that if observed signs, such as vomiting or diarrhea, are present and persist, the owner should consult with a veterinary professional. This is to ensure appropriate follow-up care is given.

Q: What happens if I accidentally take two doses of Extrontel Plus XL?

Safety studies documented in regulatory reports observed the effects of taking high amounts of the drug. These studies found that a single dose of 5 times the recommended amount or greater gave rise to occasional vomiting. No serious outcomes were reported at these high oral doses in initial toxicity studies.

Q: Can Extrontel Plus XL interact with herbal supplements like St. John's Wort?

Official documents caution against the use of substances that increase Cytochrome P-450 (CYP) enzyme activity, as these may decrease the concentration of the Praziquantel component. Specific herbal supplements are not named in the official warnings.

Q: Is it okay to drive or operate machinery while on Extrontel Plus XL?

This product is a veterinary medicine intended for use in animals, not humans. Official safety guidelines for the person administering the tablet include washing hands afterward and adherence to guidelines concerning the handling of certain parasites, such as Echinococcus spp., due to their potential hazard to humans.

Q: What does the research say about the long-term safety of Extrontel Plus XL?

Long-term safety is suggested by the drug's low toxicity observed in repeated dose studies in dogs. However, the core regulatory studies primarily assessed short-term efficacy for clearing existing infections. Concern about resistance development is a documented issue with frequent, repeated use over time.

Q: Does the time of day I take Extrontel Plus XL matter?

Official administration instructions state that fasting is neither necessary nor recommended. The product can be given directly by mouth or mixed in a small amount of food at the time of administration, with no specific instructions regarding the time of day.

Q: What is the maximum time a person can safely be on Extrontel Plus XL?

The primary administration guidelines define the use as a short-term, single-administration course. For specific risk scenarios, regulatory guidelines permit a periodic, scheduled regimen of administration, typically recommending intervals of 21 to 26 days.

Q: Does Extrontel Plus XL contain lactose or gluten?

According to the official documentation (SmPC) that lists the inactive ingredients, the product contains Lactose monohydrate as an excipient. Information regarding the presence of gluten is not typically detailed in the official excipient list.

How should Extrontel Plus XL be stored and disposed of?

How to Store and Dispose of Extrontel Plus XL

Official regulatory documents define specific conditions for storing and disposing of this product.

Storage Requirements

Storage Component	Official Regulatory Requirement
Unopened Product	Does not require any special storage conditions or specific temperature restrictions.
Shelf-Life	3 years as packaged for sale.
Divided Tablets	Shelf-life of half tablets is 14 days; must be used within this period.
Protection	Store the remaining half tablet by returning it to the open blister space and outer carton to protect from light.

Handling and Disposal

For safety, Extrontel Plus XL must be stored out of the sight and reach of children.

After administration, persons should wash their hands. Any unused divided tablets must be discarded immediately or after the 14-day limit.

Disposal instructions mandate that any unused veterinary medicinal product or waste materials should be disposed of in accordance with local requirements.

Extrontel Plus XL